Malaria is a mosquito-borne disease that can cause infected people to become very sick with high fever, chills, and flu-like illness. It can also cause death. Substantial progress has been made globally to control and eliminate malaria, but it continues to be a significant public health problem with roughly 3.2 billion people worldwide at risk for the disease.
Why Is the Study of Malaria a Priority for NIAID?
Roughly 3.2 billion people—almost half of the world’s population—are at risk of malaria, according to the World Health Organization. Although substantial progress has been made in the fight to control and eliminate malaria, the mosquito-borne disease remains a significant public health problem.
How Is NIAID Addressing This Critical Topic?
NIAID is the lead agency in the U.S. federal government supporting malaria research and development. The Institute has a longstanding commitment to malaria research to support the goals of reducing morbidity and mortality from malaria and ultimately eradicating the disease. NIAID is conducting and supporting research to better understand the disease, develop effective alternatives to mosquito control, and create diagnostics, treatments, and a vaccine to prevent infection.
NIAID Now Blog
Video: Take a Tour of the Special Clinical Studies Unit, November 16, 2018
New Directions in Mosquito Control: A Real Buzzkill, August 20, 2018
Pathogenesis of Neurodevelopmental Impairment After Severe Malaria, March 19, 2019, 5625 Fishers Lane, Rockville, Maryland 20852
Using an Amoeba to Define the Mechanism of Cannabidiol in Epilepsy Treatment, May 14, 2019, 5625 Fishers Lane, Rockville, Maryland 20852
Single particle cryo-EM of membrane proteins – channels and transporter, April 16, 2019, 5625 Fishers Lane, Rockville, Maryland 20852